RLMD (Relmada Therapeutics) Institutional Ownership : 42.98% (As of Dec. 11, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Relmada Therapeutics's institutional ownership is 42.98%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Relmada Therapeutics's Insider Ownership is 3.85%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Relmada Therapeutics's Float Percentage Of Total Shares Outstanding is 98.34%.

Relmada Therapeutics Institutional Ownership Historical Data

The historical data trend for Relmada Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Institutional Ownership Chart

Relmada Therapeutics Historical Data

The historical data trend for Relmada Therapeutics can be seen below:

	2024-01-31	2024-02-29	2024-03-31	2024-04-30	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	11.92	12.17	12.92	13.66	14.27	14.58	15.32	15.31	15.39	15.49

Relmada Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Relmada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

4E2:Germany

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Executives

Sergio Traversa	director, officer: Chief Executive Officer	138 CANTERBURY LN, BLUE BELL PA 19422
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Paul Edward Kelly	director	300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Chuck Ence	officer: Chief Financial Officer	3000 S. UNIVERSITY BLVD., DENVER CO 80210
Cedric O'gorman	officer: Chief Medical Officer	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli	director	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Thomas Wessel	officer: EVP, Head of R&D	15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Ottavio V. Vitolo	officer: Chief Medical Officer	71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar	director	P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas	officer: President and CSO	7707 GATEWAY BLVD, NEWARK CA 94560